Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Sensei Biotherapeutics, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/04/2023 SC 13G/A Cambrian BioPharma Inc reports a 14.6% stake in Sensei Biotherapeutics, Inc.
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights"
08/02/2023 4 Cambrian BioPharma Inc (10% Owner) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Disposed/sold 1,587,302 shares @ $1.26, valued at $2M
08/02/2023 4 Peyer James (10% Owner) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Disposed/sold 1,587,302 shares @ $1.26, valued at $2M
07/12/2023 4 RINGO WILLIAM R (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 RICKS THOMAS G (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Broder Samuel (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Humer Kristian (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 English Jessie (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Vojta Deneen (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Holmen Bob (Director) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Peyer James (10% Owner) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/12/2023 4 Cambrian BioPharma Inc (10% Owner) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Granted 4,466 shares @ $0
Granted 14,550 options to buy @ $1.22, valued at $17.8k
07/10/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/02/2023 4 Apeiron Investment Group Ltd. (10% Owner) has filed a Form 4 on Sensei Biotherapeutics, Inc.
Txns: Sold 2,485,923 shares @ $1.58, valued at $3.9M
Sold 955,738 shares @ $1.58, valued at $1.5M
06/02/2023 SC 13D/A Apeiron Investment Group Ltd. reports a 0% stake in Sensei Biotherapeutics, Inc.
05/23/2023 SC 13D/A Apeiron Investment Group Ltd. reports a 11.1% stake in Sensei Biotherapeutics, Inc.
05/23/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Purchase Agreement, by and among Sensei Biotherapeutics, Inc., on the one hand, and Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd., on the other hand",
"Purchase Agreement, by and among Sensei Biotherapeutics, Inc., on the one hand, and Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd., on the other hand"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights"
05/01/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/20/2023 8-K Quarterly results
03/29/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
03/29/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
03/29/2023 4/A Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
03/29/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/13/2023 8-K Investor presentation
Docs: "Sensei Biotherapeutics, Inc. corporate presentation, dated March 2023"
03/10/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy